- Home
- PNI vs BYSI Comparison
PNI vs BYSI Comparison
Compare PNI & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$1.59
Company Overview
Basic Information| Metric | PNI | BYSI |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.1M | 67.9M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | PNI | BYSI |
|---|---|---|
| Price | $6.71 | $1.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 42.0K | 21.4K |
| Earning Date | 01-01-0001 | 03-25-2026 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.43 | $0.98 |
| 52 Week High | $7.23 | $3.44 |
Technical Indicators
Market Signals| Indicator | PNI | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 23.20 | 51.88 |
| Support Level | $6.61 | $1.38 |
| Resistance Level | $6.98 | $1.83 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 2.68 | 48.98 |
Price Performance
Historical Comparison PNI
BYSI
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.